8NN Stock Overview
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Thor Medical ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.08 |
| 52 Week High | kr0.17 |
| 52 Week Low | kr0.064 |
| Beta | 0 |
| 1 Month Change | 18.81% |
| 3 Month Change | -17.08% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8NN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -18.6% | -0.2% | 0.5% |
| 1Y | n/a | -22.8% | 1.3% |
Return vs Industry: Insufficient data to determine how 8NN performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 8NN performed against the German Market.
Price Volatility
| 8NN volatility | |
|---|---|
| 8NN Average Weekly Movement | 29.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8NN's share price has been volatile over the past 3 months.
Volatility Over Time: 8NN's weekly volatility has increased from 24% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 2 | Alf Bjørseth | www.thormedical.no |
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was founded in 2009 and is headquartered in Oslo, Norway.
Thor Medical ASA Fundamentals Summary
| 8NN fundamental statistics | |
|---|---|
| Market cap | €21.16m |
| Earnings (TTM) | -€472.64k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-44.8x
P/E RatioIs 8NN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8NN income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr5.56m |
| Earnings | -kr5.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 8NN perform over the long term?
See historical performance and comparison